Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

PSMA

9 posts
NNovartis
Novartis's Fiona Marshall Says RLT Can Treat Nearly Every Tumor as Pipeline Tops 20 Candidates — BigGo Finance
Read More

Novartis’s Fiona Marshall Says RLT Can Treat Nearly Every Tumor as Pipeline Tops 20 Candidates — BigGo Finance

  • 2026-08-19
A Platform Bet on Radiation The most consequential idea in Fiona Marshall’s vision for Novartis research is also…
NNovartis
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Read More

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

  • 2026-08-01
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population PSMAddition updated results show Pluvicto…
NNovartis
Novartis Launches Prostate Cancer Radiotherapy
Read More

Novartis Launches Prostate Cancer Radiotherapy

  • 2026-06-23
The launch highlights the growing maturity of India’s nuclear medicine ecosystem. Kindly note that this illustration generated using…
NNovartis
Novartis launches prostate cancer drug
Read More

Novartis launches prostate cancer drug

  • 2026-06-16
New Delhi: Novartis India on Monday announced the launch of Pluvicto, a precision radiotherapy for prostate cancer. Pluvicto…
NNovartis
Business Standard
Read More

India gets first approved radioligand therapy for prostate cancer | Health News

  • 2026-06-15
Months after exiting its listed Indian subsidiary, Novartis has reinforced its commitment to the country’s innovation medicines…
NNovartis
Novartis launches Pluvicto®, India's first approved radioligand therapy for PSMA‑positive advanced prostate cancer, expanding precision care.
Read More

Novartis launches Pluvicto®, the Country’s First Regulatory Authority Approved Radioligand Therapy for Advanced Prostate Cancer

  • 2026-06-15
Novartis India announced the launch of Pluvicto(lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority-approved radioligand therapy for…
NNovartis
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Read More

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

  • 2026-05-31
Novartis Pharma AG Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto…
NNovartis
Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030
Read More

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030

  • 2026-02-23
Company Logo Radioligand Therapeutics in Cancer Treatment Market Radioligand Therapeutics in Cancer Treatment Market · GlobeNewswire Inc. Dublin,…
NNovartis
Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030
Read More

Radioligand Therapy Market to Surge with 13.1% CAGR: Projected Growth from $2.6B in 2025 to $4.8B by 2030

  • 2026-02-19
Company Logo Radioligand Therapeutics in Cancer Treatment Market Radioligand Therapeutics in Cancer Treatment Market · GlobeNewswire Inc. Dublin,…
Switzerland
www.europesays.com